Recently, a novel form of MSI has been described that occurs only at tetranucleotide repeat markers. This has been termed elevated microsatellite instability at selected tetranucleotide repeats (EMAST). EMAST has been related to alterations of the p53 gene, and to the nature of the repeat sequence. We initially tested whether loss of heterozygosity (LOH) at the p53 and the patched (ptch) genes was related to EMAST in a series of 61 non-melanoma skin cancer (NMSC) tumors. We then analysed a series of 57 primary bladder cancers for the presence of EMAST, testing whether this was related to mutation or expression of the p53 gene. In both NMSC and bladder tumors we found a high prevalence of EMAST (75.4 and 43.9%). In NMSC the prevalence of EMAST was higher in tumors that had either p53 or ptch LOH, although the difference was not statistically significant. There was a significant association of extensive EMAST (three or more loci) with mutations in p53 among the bladder cancer tumors, but no indication of elevated EMAST in tumors with abnormal p53 staining without mutation. The association of EMAST with p53 mutation was confined to non-invasive disease. Hence, EMAST likely reflects a particular pattern of somatic events that are interactive with p53 mutation, particularly common in skin cancer and limited to non-invasive disease in bladder cancer.
Introduction
During the malignant transformation of somatic cells there is an accumulation of genetic alterations (Fearon and Vogelstein B, 1990; Vogelstein and Kinzler, 1993) . It has been postulated that the number of somatic modifications in solid tumors is sufficiently high to necessarily involve the genesis of a genetically unstable phenotype within evolving clones (Loeb, 1991) . There are at least two mechanisms for genetic instability (reviewed in Loeb and Loeb, 2000) ; one mechanism involves alterations in genes required for chromosomal segregation and is manifested by fragmentation of chromosomes, or duplication and deletion of whole chromosomes. The second mechanism involves inactivation of DNA mismatch repair genes and is manifested by classic microsatellite instability (MSI). MSI was first observed in the study of hereditary non-polyposis colorectal cancer (HNPCC) (Boland et al., 1998) .
Recently, a distinct form of MSI was described where the instability is specific to tetranucleotide repeat regions (Boland et al., 1998; Ahrendt et al., 2000; Xu et al., 2001) . This new type of MSI has been termed 'elevated microsatellite alterations at selected tetranucleotide' repeats (EMAST) (Boland et al., 1998) . Individual cell lines and tumors with EMAST do not have MSI at mono-and dinucleotide repeats indicating that a pathway distinct from mis-match repair is involved in the generation of EMAST (Boland et al, 1998; Xu et al., 2001) . Recent work has also suggested that EMAST is associated with the sequence of the individual tetranucleotide repeat, and alterations in the tumor suppressor gene p53 (Ahrendt et al., 2000; Xu et al., 2001) .
p53 plays a prominent role in maintaining the integrity of the genome. The loss of p53 leads to a failure of cell cycle arrest, inopportune gene amplification, aneuploidy, and/or chromosome loss (Livingstone et al., 1992; Hartwell and Kasten, 1994; Sidransky and Hollestein, 1996) . These changes can lead to the accumulation of daughter cells with multiple somatic alterations characteristics of genomic instability (Kuerbitzt et al., 1992) .
NMSCs have among the highest prevalence of p53 mutation reported for epithelial tumors. Another tumor suppressor gene that is frequently altered in this cancer is the human homologue of the drosophila segment polarity gene, patched (ptch) (Gailani et al., 1992; Hahn et al., 1996; Johnson et al., 1996) . Ptch was first identified as a tumor suppressor gene through the study of the nevoid basal cell carcinoma syndrome (NBCCS) (Gailani et al., 1992; Hahn et al., 1996; Johnson et al., 1996) . Interestingly, several groups have shown that lymphocytes from NBCCS patients demonstrate elevated unscheduled DNA synthesis after radiation exposure as well as irregular cell cycle control (Nagasawa et al., 1988; Fujii et al., 1997 Fujii et al., , 1999 . Given the high prevalence of mutations in these genes in NMSC, we tested the hypothesis that p53 and ptch alterations are associated with EMAST. To further understand the relationship of these alterations and EMAST we included tumors from a prospective case series designed to examine p53 alteratoins in bladder cancers.
Results

Microsatellite instability
A total of seven tetranucleotide repeats were used to assess EMAST in NMSC and bladder tumors. Overall, tumors showing EMAST at one or more loci ranged from 43.9% (25/57) in bladder tumors to 75.4% (46/ 61) in NMSC (Table 1 ). The prevalence was lower when the data were stratified to reflect EMAST at three or more loci (31.6 and 42.6% respectively). There was no significant association of skin type, site of tumor on the body, cigarette smoking, or a history of radiation exposure with the presence of EMAST in NMSC (Table 1 ). For bladder cancer there was no significant association of EMAST and gender, age or smoking status (Table 1) . However, we did see an association of any EMAST with increasing years of cigarette smoking (P=0.02). This association was also seen in cases with extensive EMAST at three or more loci (P=0.05; Table 1 ).
Basal cell (BCC) and squamous cell (SCC) skin tumors are quite different both genetically and clinically. BCCs had significantly more EMAST than SCC (84.9 vs 65.2%; Table 2 ). This difference was strongest when considering EMAST at three or more loci (57.6 vs 26.1%; P=0.02). Analysis stratified by histology and repeat sequence revealed a significant difference for TCTA repeats. Eleven of 28 (39.3%) BCC tumors had EMAST at the TCTA loci (D5S1502) compared with one of 15 (6.7%) in squamous cell carcinomas (P=0.03). A similar analysis comparing the length of each tetranucleotide repeat revealed no significant association between EMAST and repeat length (data not shown). Finally, in an effect to determine if EMAST occurs early in the clonal evolution of NMSC we also examined EMAST in pre-malignant lesions. EMAST was present in three of five lesions, indicating that this type of instability can occur early in tumorigenesis (Table 2) .
We next examined whether EMAST was associated with either 9q22 (ptch) or 17p13 (p53) LOH in the NMSC tumors (Table 3 ). There was no significant association between EMAST and 9q22 LOH. However, the presence of EMAST tended to be more common among those with 9q22 LOH, particularly for EMAST at three or more loci, and at the GATA (D9S252 and D9S303) and TCTA (D5S1502) loci. EMAST at 9q was associated with ptch LOH (P50.04). There was no significant association of p53 LOH and EMAST (Table 3 ). Yet, overall the prevalence of EMAST was highest in tumors with any LOH (Table 3) .
Bladder tumors were selected for study based upon their p53 mutation and p53 IHC status to better investigate the relationship between p53 inactivation and EMAST (Table 4) . Three groups were identified: tumors with p53 mutation, tumors with no mutation but abnormal IHC staining, and tumors with both wild type sequence and normal IHC staining. EMAST was highest among those with p53 mutation (Table 4) . This association was borderline significant for EMAST at three or more loci (P50.07; Table 4 ). Elevated EMAST was only found among those with p53 Table 4 ). Since bladder cancers may be broadly classified as invasive or non-invasive and it has been hypothesized that invasive and non-invasive bladder cancers arise through different pathways, we stratified the p53 analysis by tumor invasiveness. The association of p53 mutation and EMAST was only evident in the non-invasive disease (Table 4) . Finally, logistic regression analysis detected significant confounding of the p53-EMAST relationship by duration of smoking. In this adjusted analysis (adjusted for duration of smoking) p53 mutation remained a significant predictor of EMAST.
Because EMAST and p53 alterations are associated, we next directly tested whether isogenic cell lines with differing p53 mutation status differed in their EMAST status. The TK6, WTK1 and NH32 cell lines have been shown to be p53 wild type, p53 mutant and p53 null, respectively (Chuang et al., 1999) . Examining the same seven tetranucleotide repeat loci, we observed no EMAST in any of the cell lines (data not shown).
Discussion
NMSC and bladder tumors demonstrate very high levels of tetranucleotide instability (75.4 and 43.9%, respectively). The prevalence of EMAST in NMSC was investigated using a population-based sample and the resulting estimate is markedly higher than that reported in non-small cell lung cancer (51%), head and neck cancer (56%), bladder cancer (21%), and kidney cancer (12%) (Xu et al., 2001) . EMAST in bladder tumors was higher in our series compared to Xu et al. (2001) . This likely reflects our selection of tumors for study based upon their p53 status. It is possible that the high prevalence of EMAST in both NMSC and bladder cancer is the result of a common repair mechanism defect and/or the alteration of a locus that generates this genomic instability within these tumors.
Alteration of p53 is a common event in many cancers. Given its role in maintaining genomic stability, it is possible that altered p53 might play a mechanistic role in the genesis of EMAST. In fact, a recent report from Ahrendt et al. (2000) found that tumors with EMAST also had mutations in the tumor suppressor gene p53. In NMSC tumors there was a higher EMAST prevalence with p53 LOH, although this trend did not reach statistical significance. Thus, these data do not exclude the possibility that altered p53 status is related to EMAST in NMSC, particularly since the p53 status in these tumors was not completely characterized.
Similarly, in bladder cancer, where complete p53 data were available, there was a borderline significant association of p53 mutation and EMAST. The fact that elevated EMAST was not present in the IHC positive tumors indicates it is likely the mutation event in the gene and not an abnormal p53 pathway is associated with this type of instability. This is consistent with the observation that EMAST is associated with duration of smoking; tobacco smoking also induces p53 mutation and duration of smoking is a clear confounder in the analysis of the p53 mutation association with EMAST. At the same time, the data using human lymphocyte cell lines that differ only in their p53 status demonstrate p53 abrogation is not sufficient to induce EMAST. Other alterations are almost certainly necessary and these are also likely associated with the duration each patient smoked. Indeed, the association of p53 mutation with EMAST in non-invasive bladder cancers further suggests that additional somatic alterations (other than p53 mutation) are responsible for both the maintenance of the non-invasive phenotype and the enhanced likelihood of EMAST occurrence.
p53 is commonly described as a gatekeeper for genomic instability. An alternative hypothesis is that p53 deficiency is necessary but not sufficient to induce chromosomal instability (Lu et al., 2001) . Tumors that do not have a functional p53 response because of a p53 mutation may be tolerant of tetranucleotide instability. In animal studies it has been shown that p53 deficiency is required to propagate chromosome instability but that the p53 alteration itself is not the driving force (Lu et al., 2001) . In many cancers the p53 response is impaired late in tumorigenesis. However, in histologically normal UV-exposed skin, fields of p53 mutated cells are detectable indicating p53 alteration is early in NMSC (Ren et al., 1997; Ouhtit et al, 1998) . If these cells propagate with a permissive p53 background an increase in genetic instability would be expected. This could account for the very high frequency of EMAST within NMSC tumors compared to other cancers. The tumor suppressor gene patched (ptch) is frequently altered in NBCCS as well as in sporadic BCC and to a smaller extent SCC (Gailani et al., 1992; Hahn et al., 1996; Johnson et al., 1996; Ahmadian et al, 1998) . Ptch is believed to be a gatekeeper gene in the development of BCC . Nagasawa et al. (1988) have shown that fibroblasts from NBCCS patients with constitutional mutations in the ptch gene have a diminished capacity for DNA repair as well as overall genomic instability. More recently, others have shown that NBCCS patient lymphocytes have deregulated cell cycle control and abnormal DNA synthesis (Fujii et al., 1997 (Fujii et al., , 1999 . However, we found no association with ptch LOH and the presence of EMAST in the NMSC tumors.
Mutations or alterations generated by genetic instability are initially likely to be random events. Only a selected few lesions would result in a growth advantage sufficient to generate a clonal population of cancer cells (Loeb and Loeb, 2000) . The presence of EMAST clearly indicates that the instability arises in single cells that clonally expand. However, precisely how these clonal cells with novel repeat lengths are selected is unclear. One hypothesis is that tetranucleotide repeats could contribute to the formation of stable secondary structures that lead to unequal recombination events between homologous alleles and sister chromatids (Gibbs et al., 1993) . The process of LOH has been shown to occur not only by simple deletion events but also through this recombinational process (Little, 2000) . Therefore, it is possible that LOH and EMAST may often be concurrent events. Consistent with this, we observed higher levels of EMAST in tumors with LOH. In addition, there was a significant association of ptch LOH and EMAST at 9q22, supporting the notion that these events may be related in time through aberrant recombination. Continued investigation into the EMAST phenotype and the different components of genomic instability may help in understanding this new form of MSI.
Materials and methods
Study population
NMSC cases were identified from an incident survey of all newly diagnosed BCC and SCC in New Hampshire (Karagas et al., 1999) . Bladder cancer cases were identified by a rapid reporting system of the New Hampshire State Cancer Registry (Karagas et al., 1998) . Study participants completed an extensive administered questionnaire to obtain information on demographic traits and carcinogen exposure (described in Lichter et al., 2000) . Pathology reports and paraffin-embedded tumor specimens were requested from the treating physician/pathology laboratories. Bladder tumors were reviewed by one pathologist and classified according to the WHO classification of bladder tumors. Skin tumors were similarly reviewed and pathology confirmed. Three 20-micron sections were cut, and DNA was extracted as described by Nelson et al. (1998) . At the time of interview a circulating peripheral blood sample was taken and DNA extracted using Qiamp kits (Qiagen).
Cell lines
Three isogenic cell lines with differing p53 status were provided by Dr Howard Liber (Colorado State University). Cells were grown in RPMI 1640 media (Mediatech), supplemented with 10% fetal horse serum (Sigma) and penicillin/streptomycin (Mediatech). DNA was isolated from the cells using a Qiamp DNA purification kit (Qiagen).
p53 mutation analysis SSCP analysis of p53 exons 5 through 9 was performed on all bladder tumor samples. Exons were amplified by PCR containing fluorescence dye labeled primers and analysed by a DNA autosequencer ABI 377(PE Applied Biosystems). Previously reported primer sequences and annealing temperatures for each exon were used (Toguchida et al., 1992) . Samples with variant SSCP bands were directly sequenced by a DNA auto-sequencer ABI 377 using BigDye Terminator v3.0 (PE Applied Biosystems).
p53 immunohistochemistry
Immunohistochemical staining of paraffin-embedded slides was performed using the avidin-biotin complex technique. For each case, a single representative slide was selected for staining and histologic evaluation. Briefly, slides were deparaffinized and hydrated into water. Slides underwent antigen retrieval in Citra solution using the Biocare Decloaking Chamber (Biocare Medical). Staining of p53 was performed using a monoclonal antibody (BioGenex) at a 1:100 dilution on the Optimax I-6000 Immunostainer (BioGenex). An appropriate positive control was used in each staining run, and each slide was stained with a negative control.
The intensity of nuclear staining was graded on a semiquantitative scale (0 -3). In addition, the precentage of positively staining tumor cells was scored (negative, 1 -9%, 10 -49%, or 450%). Three different groups of tumors were selected: (1) those with p53 mutation confirmed by sequencing without regard to IHC status; (2) those with no detected mutation and an IHC intensity score of three with greater than 50% of the specimen staining positive; and (3) those with no detected mutation and an IHC intensity score 51 with positive staining in less than 10% of the tumor.
Microsatellite analysis
Microsatellite analyis was performed on 62 tumors using a panel of seven tetranucleotide repeat markers (D9S252, D9S303, D7S1482, D20S82, D7S1485, D9S242, D5S1502). Four dinucleotide repeat markers (D9S15, D9S53, D17S513, D17S1176) were used to assess LOH. Fluorescent dye labeled primer pairs for each locus were obtained from Research Genetic's MapPair list (Research Genetics). Each PCR mixture contained 1.5 ml of template DNA, 12.5 pmol of each primer, 0.2 mM dNTPs, 1 ml of 106reaction buffer, and 1.25 units of AmpliTaq (PE Applied Biosystems) in a final solution of 12.5 ml. Amplification was done following the conditions of Shen et al. (1999) , with a varying annealing temperature for each loci being studied. Briefly, 40 cycles of amplification were performed: 948C for 40 s, annealing at 55 -648 (depending on primer set) for 1 min and extension at 728 for 1 min. A final extension at 728 was done for 10 min.
Amplified PCR products were run on 4% denaturing polyacrylamide gel for the ABI PRISM 377 (PE Applied Biosystems) with a labeled marker (TAMRA 350) as an internal size standard. The data was then analysed with the Genescan 2.1 software (PE Applied Biosystems).
Criteria for EMAST and LOH
For each locus LOH and instability were assessed using the Genescan program (PE Applied Biosystems). The criteria used for EMAST (+) was the appearance of new or novel peaks in the tumor samples that were not present in the corresponding constitutional DNA sample (Figure 1) . LOH was determined for those dinucleotide loci that were heterozygous. The allelic ratio (AR) was derived as the ratio of the peak heights in the blood-derived samples divided by the peak heights of the alleles from the tumor. Ratio values of 50.5 or 41.5 were taken to be indicative of LOH.
Statistical analysis
The association of patient demographics, tumor traits, and LOH at 9q22 and 17p13 with EMAST was assessed using non-parametric tests (Fisher's exact test, Wilcoxon rank-sum and the test of trend) and logistic regression, as indicated. All P values represent two-sided statistical tests with statistical significance at P50.05.
